RE: Pharmacoeconomic simulations
Peter,
Pharmacoeconomic means different things to different people, and the
following references should cover a useful spectrum
Poland B, Wada R. Combining drug-disease and economic modelling to
inform drug development decisions Drug Discovery Today. November
2001;6(22):1165-1170.
Korsan B, Dykstra K, Pullman W. Transparent Trade-Offs: A Clinical
Utility Index (CUI) Openly Evaluates a Product's Attributes - and Chance
of Success Pharmaceutical Executive. March 2005.
Poland B, Hodge F, Khan A, Clemen R, Dykstra K, Krishna R. The Clinical
Utility Index as a Practical Multiattribute Approach to Drug Development
Decisions (Accepted 2009)
Dykstra K, Hodge F, Carrothers TJ, Korsan B. Linking Modeling &
Simulation, Decision Analysis, and the Technology of Drug Formulation
American Conference on Pharmacometrics (ACoP); March 9-12, 2008; Tucson,
Arizona
Hodge F, Using the Clinical Utility Index (CUI) to Inform Dose Selection
Decisions; Webinar February 2009;
http://www.pharsight.com/events/eventsonline_archive.php#replay_028
Korsan B, Modeling and Decision Analysis to Support Formulation
Selection and Trial Sequencing, Webinar April 2006
http://www.pharsight.com/events/eventsonline_archive.php#replay_003
Cheers -Jon
Quoted reply history
________________________________
From: [email protected] [mailto:[email protected]]
On Behalf Of [email protected]
Sent: Thursday, April 23, 2009 4:39 PM
To: Bonate, Peter; [email protected]
Subject: Re: [NMusers] Pharmacoeconomic simulations
A clinical utility index (CUI), as described recently by Ouellet et al.
Clinical Pharmacology & Therapeutics (2009); 85, 3, 277-282 as well as
by others elsewhere, is amenable to being used as a pharmacoeconomic
vehicle. Typically the CUI is derived in terms of patient benefit:risk,
but could easily be adapted to other tangible measures of value.
Jeff
"Bonate, Peter" <[email protected]>
Sent by: [email protected]
23-Apr-2009 10:37
To
[email protected]
cc
Subject
[NMusers] Pharmacoeconomic simulations
Is anyone aware of any papers or abstracts using computer-assisted trial
design that incorporates a pharmacoeconomic component to the simulation?
Or any pop pharmacokinetic-pharmacodynamic papers that include the same?
Thanks
Pete bonate
Peter L. Bonate, PhD, FCP
Genzyme Corporation
Senior Director
Clinical Pharmacology and Pharmacokinetics
4545 Horizon Hill Blvd
San Antonio, TX 78229 USA
[email protected] <mailto:[email protected]>
phone: 210-949-8662
fax: 210-949-8219
crackberry: 210-315-2713
"Beware of geeks bearing formulas". Written by Warren Buffet as part of
Berkshire Hathaway's 2009 Annual Report to Stockholders.
<<image001.gif>>